Disease-related burden and long-term outcome in orofacial granulomatosis: observations from a large single-centre cohort

Clin Exp Dermatol. 2022 Jun;47(6):1169-1173. doi: 10.1111/ced.15124. Epub 2022 Mar 16.

Abstract

There is a lack of standardized treatment recommendations for orofacial granulomatosis, a chronic inflammatory condition aetiologically related to Crohn disease. To assess clinical baseline parameters and treatment strategies, we retrospectively analysed 61 consecutive cases from our institutional database. Disease-related functional/psychological impairment and long-term outcomes were descriptively evaluated using a standardized self-reporting questionnaire. The median age of patients was 45 (7-77) years. Oral steroids were given in 41.0% of cases, but only produced short-term disease control, while response to steroid-sparing agents was inconsistent. Only a minority of patients reported relevant disease-related functional impairment in eating (21.7%) or speaking (4.3%), but the majority perceived psychological distress due to the cosmetic aspects of the disease (69.6%), comments from others (65.2%) and/or general anxiety/insecurity (73.9%). Regardless of the initial treatment, long-term outcomes after 71 months (range 7-304 months) were beneficial, with most patients being in complete remission (52.2%) or reporting only mild residual swelling (43.5%).

MeSH terms

  • Aged
  • Cost of Illness
  • Crohn Disease* / drug therapy
  • Granulomatosis, Orofacial* / drug therapy
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Steroids / therapeutic use

Substances

  • Steroids